Search

Pliant Therapeutics Prices IPO, Lands $144M to Test Fibrosis Drugs

PLIANT THERAPEUTICS PRICES IPO, LANDS $144M TO TEST FIBROSIS DRUGS

Pliant Therapeutics is now a public company, raising $144 million from its IPO, plus more from a separate transaction with partner...

BIOTECH IPO BONANZA: LEGEND'S $350M OFFERING AS REPARE, FORMA GET IN ON THE ACTION

Biotech IPO bonanza: Legend's $350M offering as Repare, Forma get in on the action badams Mon, 06/01/2020 - 06:40

 
 
 
Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs

FORMA THERAPEUTICS EYES IPO TO ADVANCE SICKLE CELL, PROSTATE CANCER DRUGS

Forma Therapeutics has developed a pipeline of small molecules aimed at rare blood disorders and cancers, but it aims to advance two-investigational...

Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem's Approval & More

BIO ROUNDUP: ASCO OPENS, MERCK TAKES ON COVID, EVOFEM'S APPROVAL & MORE

A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual...

 
 
 
Peet's Coffee raises $2.5 billion in an IPO despite the coronavirus pandemic

PEET'S COFFEE RAISES $2.5 BILLION IN AN IPO DESPITE THE CORONAVIRUS PANDEMIC

Peet's Coffee raised $2.5 billion in its initial public offering, one of the largest this year despite the coronavirus pandemic. The...

Starling's plan to reach profitability in early 2021 and launch an IPO have been delayed by the coronavirus

STARLING'S PLAN TO REACH PROFITABILITY IN EARLY 2021 AND LAUNCH AN IPO HAVE BEEN DELAYED BY THE CORONAVIRUS

Business Insider Intelligence and eMarketer are now Insider Intelligence , a digitally-focused research company from Insider Inc. Learn...

 
 
 
Warner Music Group resurrects its $1.8 billion IPO plan after canceling deal on coronavirus risks

WARNER MUSIC GROUP RESURRECTS ITS $1.8 BILLION IPO PLAN AFTER CANCELING DEAL ON CORONAVIRUS RISKS

Warner Music Group plans to list 70 million shares on the Nasdaq exchange, reviving IPO plans that were first canceled amid the coronavirus...

 
 
 
Shopify stock has skyrocketed 4,600% since the e-commerce giant went public 5 years ago

SHOPIFY STOCK HAS SKYROCKETED 4,600% SINCE THE E-COMMERCE GIANT WENT PUBLIC 5 YEARS AGO

AP/Denis Poroy Shopify stock has surged nearly 4,600% since the company's IPO five years ago. The e-commerce group priced its shares...

Applied Molecular Plots IPO to Back Transport of Biologic Drugs to Gut

APPLIED MOLECULAR PLOTS IPO TO BACK TRANSPORT OF BIOLOGIC DRUGS TO GUT

The human gut hosts a hub of activity spanning the immune system, the nervous system, and more. But drugging this nexus comes with...

 
 
 
Owner of Peet's Coffee plans $2.2 billion IPO

OWNER OF PEET'S COFFEE PLANS $2.2 BILLION IPO

Alex Tai/SOPA Images/LightRocket via Getty Images JDE Peet's, owner of a number of coffee brands including Peet's Coffee, plans to...

Mythic Markets Offers a Chance to Own Piece of a Sealed 'Magic: The Gathering' 94 Booster Box Set

MYTHIC MARKETS OFFERS A CHANCE TO OWN PIECE OF A SEALED 'MAGIC: THE GATHERING' 94 BOOSTER BOX SET

Pop culture investment platform and community Mythic Markets recently launched its latest IPO, offering fans a piece of a sealed Magic:...

 
 
 
Bio Roundup: FDA Dings BMS, Genfit's Fall, Alexion's Activist & More

BIO ROUNDUP: FDA DINGS BMS, GENFIT'S FALL, ALEXION'S ACTIVIST & MORE

This was a disappointing week for at least two major drug makers. French firm Genfit reported a trial failure in an intensely competitive...

 
 
 

J&J-BACKED CAR-T BIOTECH LEGEND GUNS FOR $100M IPO BUT SEES CRS DEATH IN EARLY TRIAL

Legend Biotech is hoping it can ride the biotech IPO wave and take in a cool $100 million for its cell therapy work.

 
 
 
Ayala's IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs

AYALA'S IPO RAISES $55M TO TEST TWO FORMER BRISTOL MYERS CANCER DRUGS

Ayala Pharmaceuticals has two clinical-stage cancer drugs licensed from Bristol Myers Squibb. Now it has $55 million to take those...

 
 
 
Bio Roundup: Remdesivir Data, Erasca's $200M, a New FDA Nod & More

BIO ROUNDUP: REMDESIVIR DATA, ERASCA'S $200M, A NEW FDA NOD & MORE

Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized...